Goodwin Procter advised MOMA Therapeutics on the deal. MOMA Therapeutics announced its completion of a $150 million Series B Financing. MOMA Therapeutics is a biopharmaceutical company...
MOMA Therapeutics’ $150 Million Series B Financing
Femasys’ $34.45 Million IPO
Goodwin Procter advised the underwriters on the deal, while Dechert advised Femasys. Chardan, a global investment bank, announced that it acted as lead left bookrunner in...
Privia Health Group’s $607.8 IPO
Goodwin Procter LLP advised the underwriters on the deal. Privia Health Group, Inc. (“Privia Health”) (Nasdaq: PRVA), a technology-driven, national physician enablement company that collaborates with...
Rubius Therapeutics’ $200 Million Underwritten Public Offering
Goodwin Procter LLP advised Rubius Therapeutics on the deal. Rubius Therapeutics (NASDAQ: RUBY) announced the upsized underwritten public offering of 6,896,552 shares of its common stock at...